Navigation Links
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Date:10/25/2007

DEERFIELD, Ill., Oct. 25 /PRNewswire/ -- Astellas Pharma US, Inc. today announced data demonstrating that VAPRISOL(R) (conivaptan hydrochloride injection) effectively raises serum sodium concentration ([Na+]) and is well-tolerated among hospitalized patients with euvolemic or hypervolemic hyponatremia, a potentially life-threatening condition that occurs when the body's sodium level falls below normal. The efficacy and safety profile of VAPRISOL was comparable under double-blind or open-label conditions. The study results were presented at the American College of Chest Physicians (CHEST) 2007 meeting.

"Hyponatremia is common in patients with congestive heart failure and in patients with the syndrome of inappropriate antidiuretic hormone (SIADH), which is seen in various pulmonary disorders and postsurgical settings," said Joseph G. Verbalis, M.D., at the Georgetown University Hospital. "These data suggest that VAPRISOL can safely and effectively raise serum sodium levels in patients with underlying conditions such as pneumonia, chronic obstructive pulmonary disease and impaired heart function."

VAPRISOL is the first in a new class of arginine vasopressin (AVP) receptor antagonists. VAPRISOL blocks both V1a and V2 vasopressin receptors, resulting in increased urine output without increased sodium loss. This effect, known as "aquaresis," increases serum sodium levels and helps to restore salt and water balance in patients with hyponatremia due to increased body water (dilutional hyponatremia).

VAPRISOL is approved by the U.S. Food and Drug Administration as a treatment for euvolemic and hypervolemic hyponatremia in hospitalized patients. VAPRISOL is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events. The approved doses for VAPRISOL include 2
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...s treated at the initial dose in an ongoing Phase ...d decline after three days , , Conference Call ...ewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc....e first cohort of an ongoing Phase Ib clinical tri...cleoside polymerase inhibitor. ANA598 was very we...
(Date:1/7/2009)..., Tenn., Jan. 7 Scienti...ct a high likelihood of relapse in children with a...searchers caution that further research is needed ...1 or IKAROS, lead to leukemia relapse, the find...agnostic tests to assess the risk of treatment fai...
(Date:1/7/2009)...CK, Md., Jan. 7 ImQuest Life Scien...n IND application to the Food and Drug Administrat...ad pyrimidinedione HIV inhibitor IQP-0410. ImQuest...he first quarter of 2009. IQP-0410 is a novel smal...s a nonnucleoside reverse transcriptase inhibitor ...
(Date:1/7/2009)..., Jan. 7 Tiantan Puhua Hospital St... the worldwide leader in using stem cells to effec...ay six new globally experienced additions to its m...d the hospital,s treatment capabilities for growin...six senior doctors include the distinguished Dr. J...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 1Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 2Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 3Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 4Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 5Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 6Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 7Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 8The American Journal of Nursing honors Jean and Ric Edelman 28137 1The American Journal of Nursing honors Jean and Ric Edelman 28137 2The American Journal of Nursing honors Jean and Ric Edelman 28137 3Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 1Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 2Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 3Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 4mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 1mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 2mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 3mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 4mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 5mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 6
... protein,protects human pancreatic cancer cells fr... of the body,s natural defenses against,out-of-con... Texas,M. D. Anderson Cancer Center report in the ...otein tissue transglutaminase, known by the abbrev...rs at M. D. Anderson and,elsewhere to be overexpre...
...cal studies have,shown (1) similar rates of neurol... patients being treated with Tamiflu compared to,t...urthermore,recent data derived from US health ins...00 influenza patients treated with Tamiflu,and ove...ve shown,that the Tamiflu treated patients showed ...
Other Medicine Technology:Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3New Data from the US and Japan Support: No Established Causal Link,Between Neuropsychiatric Symptoms and Treatment with Tamiflu US,Databases Indicate Psychiatric Symptoms Lower in Influenza Patients,Taking Tamiflu Versus Those Not Taking Tamiflu 2New Data from the US and Japan Support: No Established Causal Link,Between Neuropsychiatric Symptoms and Treatment with Tamiflu US,Databases Indicate Psychiatric Symptoms Lower in Influenza Patients,Taking Tamiflu Versus Those Not Taking Tamiflu 3New Data from the US and Japan Support: No Established Causal Link,Between Neuropsychiatric Symptoms and Treatment with Tamiflu US,Databases Indicate Psychiatric Symptoms Lower in Influenza Patients,Taking Tamiflu Versus Those Not Taking Tamiflu 4
(Date:1/8/2009)..., Md., Jan. 8 Hanger Or...announce that throughout the fourth quarter of 200... Center, Rocky Mountain Orthotic-Prosthetics Cente...nc., First Coast Orthotics & Prosthetics, and ...uisitions add patient care centers to existing mar...
(Date:1/8/2009)...FRANCISCO, Jan. 8 Mediva... David Hung, M.D., president and chief,executive ...an Healthcare,Conference on Wednesday, January 14...ancis Hotel in San Francisco. , Dr. Hung wi...cal,development programs for Dimebon for Alzheime...
(Date:1/8/2009)...E, Md., Jan. 8 A new ed...ice and guidance on drugs, biological products and...search and Quality,s Centers for Education and Res...ed network of more than a dozen leading research c...Advisory Information Network ( CHAIN ) http://www...
(Date:1/8/2009)...ne Promoted to Principal. Christine Siu and Jason...NNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn., Jan...., a health care venture capital firm that invests ...today announced the promotion of three members of ... to Principal. Christine Siu and Jason Brown have...
Breaking Medicine News(10 mins):Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2
...be treated by using state-of-the-art gene therapy ...field have developed a way of blasting DNA into ce...in caused when the heart is starved of blood due t...t may precede a heart attack. In many cases this i...
...f inheritable genes to enable people to produce mo...ttitudes to family relationships and on being huma...spiring parents with inheritable diseases hold out...offers them the possibility of avoiding passing di...
...p forward in dissecting the pathways and mechanism...hers of Yale University have seen a break through ...e adult onset Type II Diabetes mellitus. The...g a gene that produces the enzyme called Akt2 or /...
...rchers, patients suffering from Angina may have so...rapy or doses of antibiotics. Angina, a common car...all over the world, is severe chest pain caused by...od to the heart during// physical activity. Curren...
Other Medicine News:Health News:Perfect babies boon or a bane? 2Health News:Breakthrough in Type II Diabetes 2Health News:Antibiotic, Gene Therapy Help Treat Angina 2Health News:Antibiotic, Gene Therapy Help Treat Angina 3
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
Medicine Products: